Introduction {#s1}
============

The transplantation of hematopoietic stem cells (HSCs) is the only stem cell--based therapy routinely used in clinical medicine. HSC transplantation is employed for the treatment of leukemia and rare genetic defects in the blood cell compartment. Autologous bone marrow transplantation is a standard procedure to increase the therapeutic window of cytotoxic drugs ([@B3]). It is of obvious therapeutic relevance if engraftment of hematopoietic stem cells can be stimulated. In vivo HSCs need a signal transduced via G*α*~s~ to populate the bone marrow niche ([@B1]). G*α*~s~ can be constitutively activated by cholera toxin: Cholera toxin ADP-ribosylates the catalytic arginine, which is required for GTP-hydrolysis and the resulting deactivation of G*α*~s~ ([@B11]). Enhanced engraftment was indeed observed after pretreatment of HSCs with cholera toxin ([@B1]). Murine and human hematopoietic stem and progenitor cells (HSPCs) express several types of the four G protein-coupled E prostanoid receptors (EP~1--4~). Pretreatment of HSPCs with 16,16-dimethyl-PGE (dmPGE~2~) enhances their subsequent engraftment ([@B24]; [@B18]; [@B8]). This effect is presumably mediated by canonical G*α*~s~-dependent signaling: The cAMP-induced activation of protein kinase A synergizes with Wnt-dependent signals to stabilize *β*-catenin ([@B15]). Early clinical data for dmPGE~2~ are promising ([@B10]). However, de novo drug development is often impeded by unforeseeable issues of safety, pharmacokinetic variability, interactions, etc. Accordingly, the development of a new compound can encounter many obstacles ([@B40]), which drive up the costs and delay entry into late stage clinical phases. An alternative approach is to repurpose established drugs. The present study was designed to test whether treprostinil was suitable to enhance hematopoietic stem cell engraftment. Treprostinil is a stable analog of prostacyclin, it was approved for the treatment of pulmonary hypertension some 13 years ago under the brand name Remodulin. Thus, its human pharmacology and its safety profile are well known. In contrast to dmPGE~2~, treprostinil is only a low affinity agonist at inhibitory (i.e., G~i~-coupled) EP~3~-receptors; furthermore it also stimulates EP~2~- and EP~4~-receptors in addition to I prostanoid receptor (IP receptor) ([@B37]). In our description we adhere to the currently recommended receptor nomenclature, where e.g., EP~2~ and EP~4~ receptors are predominantly coupled to G~s~ ([@B4]). Hence, by engaging multiple G~s~-coupled receptors, treprostinil may be more efficacious than other prostanoids. Finally, treprostinil is metabolically stable; this allows for exploring whether in vivo administration of prostanoids offers an advantage over sole in vitro treatment with PGE~2~ or modified versions thereof ([@B25]; [@B17]). It should therefore be feasible to repurpose treprostinil for improving hematopoietic stem cell transplantation. Our experiments confirmed this conjecture: When combined with forskolin, treprostinil caused a substantial increase in cAMP levels in (murine and human) HSPCs. This translated into enhanced bone marrow reconstitution by HSPCs, which had been pretreated with the combination of forskolin and treprostinil, in lethally irradiated recipient mice. Importantly, the beneficial effects were further augmented by an additional in vivo administration of treprostinil.

Materials and Methods {#s2}
=====================

 {#s3}

### Materials. {#s4}

Treprostinil (Remodulin; United Therapeutics Corporation, Durham, NC) was provided by SciPharm SàRL (L-2540 Luxembourg City, Luxembourg); dmPGE~2~, iloprost, and beraprost were purchased from Cayman Chemicals (Ann Arbor, MI). Ro-20-1724 was obtained from Calbiochem/EMD Millipore (Darmstadt, Germany). \[^3^H\]Adenine was from PerkinElmer (Boston, MA). The Lineage Cell Depletion Kit was from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany); Human Cord Blood CD34 Positive Selection Kit, StemSpan serum-free expansion medium (SFEM), and MethoCult were from STEMCELL Technologies (Vancouver, BC, Canada); X-VIVO 15 from Lonza (Basel, Switzerland). Growth factors and cytokines required for cell culture were from PeproTech (Vienna, Austria). Chemicals and antibodies for flow cytometric analysis, FACSCanto II, and FACSDiva Software were obtained from BD Biosciences (Schwechat, Austria). The antibodies against human C-X-C motif chemokine receptor 4 (CXCR4) (12G5; allophycocyanin-labeled), human CD34 (4H11-antibody FITC-labeled), murine CD45.1 (A20; phycoerythrin-labeled), and murine CD45.2 (104; FITC-labeled) were from eBioscience (San Diego, CA); recombinant human stromal cell--derived factor-1 (rhSDF-1), and recombinant murine SDF-1 were purchased from R&D Systems, Inc. (Minneapolis, MN). AMD3100 was from Abcam (Cambridge, UK) and the two-chamber-Transwells (6.5-mm diameter, 5.0 *μ*m pore) was obtained from Corning Life Sciences (Tewksbury MA). Isobutylmethylxanthine, forskolin, pertussis toxin, cholera toxin, and TRI Reagent, and all other chemicals were from Sigma-Aldrich (St. Louis, MO).

### Isolation of Murine and Human HSPCs. {#s5}

Bone marrow cells were flushed from the femora and tibiae of donor mice. Erythrocytes were lysed. Lineage Cell Depletion Kit was used to separate lin^--^ and lin^+^ with magnetic beads. Human CD34^+^ cells were harvested from umbilical cord blood of healthy male and female donors ([@B31]), using Human Cord Blood CD34 Positive Selection Kit.

### Preincubation of HSPCs. {#s6}

HSPCs were pretreated in vitro with the combination of 10 *μ*M treprostinil and 30 *μ*M forskolin in the presence of growth factors for 1 hour: The medium for murine HSPCs was StemSpan SFEM containing 0.5 mg l^−1^ benzylpenicillin and streptomycin, 50 ng ml^−1^ each murine stem cell factor, human FLT3, interleukin (IL)-11, and 150 ng ml^−1^ murine IL-3. The medium for human HSPCs was X-VIVO 15 medium supplemented by 50 ng ml^−1^ each of human FLT3, thrombopoetin, and stem cell factor. Unstimulated control cells were also kept in the respective media containing these growth factors. For determining cAMP formation, murine or human HSPCs were incubated with either treprostinil (10 *μ*M) or dmPGE~2~ (10 *μ*M), alone or in combination with forskolin or with iloprost or beraprost (30 *μ*M each) alone or in combination with forskolin for 30 minutes. Cholera toxin (CTX; 10 *μ*g ml^−1^) was used as positive control. Chemotaxis to SDF-1 (100 ng ml^−1^) was tested after in vitro pretreatment of HSPCs in the absence and presence of the combination of 10 *μ*M treprostinil and 30 *μ*M forskolin for 1 hour at 37°C followed by washing steps. AMD3100 was added at a final concentration of 10 *μ*M.

### Reverse Transcriptase and Polymerase Chain Reaction. {#s7}

The mRNA from murine and human HSPCs, murine brain cells, human prostate cancer cell line PC3, and human colon cancer cells HCT116 ([@B13]; [@B21]) was isolated using TRI Reagent. The mRNA was reverse transcribed to cDNA with RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Vienna, Austria). Polymerase chain reaction (PCR) amplification was performed with PerfectTaq DNA Polymerase (5 Prime, Gaithersburg, MD) in 45 cycles (denaturation for 30 seconds at 94°C, annealing for 30 seconds at 55°C, extension for 90 seconds at 72°C, followed by a final extension for 5 minutes at 72°C). Specific amplicons for IP, D prostanoid receptor isoform 1 (DP~1~), and EP~1--4~ receptors and CXCR4 were electrophoretically resolved on an agarose gel. Internal controls comprised amplicons of glyceraldehyde-3-phosphate dehydrogenase and *β*-actin, which were also amplified in 45 cycles under the same conditions. Quantitative PCR (qPCR) was performed using Maxima SYBR Green/ROX qPCR Master Mix (2X) (ThermoFisher Scientific, Vienna, Austria), equal amounts of cDNAs and primers (0.1 *μ*M) in a final volume of 20 *μ*l (15-second denaturation at 95°C, annealing at 60°C for 30 seconds, extension 72°C for 30 seconds). Human and murine hypoxanthine phosphoribosyltransferase-1 (HPRT1) (cycle thresholds at ∼29 and 33 cycles, respectively) were used as reference genes for qPCR. Primer efficiency was verified by serial dilution of the template. Each reaction was performed in triplicate. Relative abundance was calculated using the 2^--ΔCt^ method (gene-specific expression level relative to that of the reference gene). Amplification was done for 45 cycles, cycle thresholds were reached after about 33/32, 31/36, 31/33, 30/33, and 30/36 for human/mouse EP1, EP2, EP3, EP4, and IP receptors, respectively, and after 30 and 31 cycles for the human and murine HRPT1, which were the reference transcripts. The specific primer pairs listed in [Table 1](#T1){ref-type="table"} were purchased from Microsynth AG (Balgach, Switzerland).

###### 

Primer pairs for PCR-mediated amplification of prostanoid and CXCR4 receptors

             Primer Forward (5′--3′)   Primer Reverse (5′--3′)   bp
  ---------- ------------------------- ------------------------- -----
  mEP~1~     AGCAGGAGCCAAGTTCCAG       CATCCGCTAGGCTCAGGTTA      106
  mEP~2~     TTATGACCATCACCTTCGCC      TAAAAACCGAAGAGCTCGGA      110
  mEP~3~     TGGATCCCTGGGTTTATCTG      GGGAAACAGGTACTGCAATGA     102
  mEP~4~     TCTCTGGTGGTGCTCATCTG      TGCAAATCTGGGTTTCTGCT      107
  mIP        GGGCACGAGAGGATGAAGT       GATGGCCTGAGTGAAGCCT       107
  mDP~1~     AAGGCTCCATAGTACGCACG      CTCAGACTACAGGCACGGGT      129
  mHprt~1~   TTTTCCAAATCCTCGGCATA      CTTCCTCCTCAGACCGCTTT      146
  hEP~1~     GAGAGCCAGGGCGCAGT         GCAAGGGCTCATGTCAGG        101
  hEP~2~     CCACCTCATTCTCCTGGCTA      TTTCCTTTCGGGAAGAGGTT      101
  hEP~3~     AGCGACCATTTGGAAAGATG      TGATGTGATCCTGGCAGAAA      93
  hEP~4~     TTACTCATTGCCACCTCCCT      CGCTCCAAACTTGGCTGATA      95
  hIP        GTGTGCTCCCTGCCTCTC        GGGGTTGAAGGCGTAGAAG       108
  hDP~1~     CGGAGGTCTTCTGCTTCTTC      CACTATGTGTTCTCTGCCCG      99
  hCXCR4     AGGAAGCTGTTGGCTGAAAA      CTCACTGACGTTGGCAAAGA      96
  hHprt~1~   CACCCTTTCCAAATCCTCAG      CTCCGTTATGGCGACCC         112

### \[^3^H\]cAMP Accumulation. {#s8}

The adenine nucleotide pool of murine or human HSPCs was metabolically labeled by incubation in medium containing \[^3^H\]adenine (1 *μ*Ci ml^−1^) for 16 hours. In some instances cells were also preincubated in the presence of pertussis toxin (100 ng ml^−1^). The cells were then pelleted and resuspended in medium containing phosphodiesterase inhibitors Ro 20-1724 and isobutylmethylxanthine at 100 *μ*M and 125 *μ*M, respectively. The accumulation of cAMP was stimulated by the addition of prostanoid receptor agonists and forskolin (see above). After 30 minutes, the cells were spun down and lysed in ice-cold 2.5% perchloric acid containing 0.1 mM cAMP for 1 hour at 4°C. After neutralization with 4.2 M potassium hydroxide, ATP and cAMP were separated by sequential chromatography ([@B22]; [@B7]). The accumulated \[^3^H\]cAMP was quantified by liquid scintillation counting. Each experiment was performed in triplicate.

### Cell Viability, Cell Cycle Distribution, and Colony Formation. {#s9}

Human or murine HSPCs were incubated in the presence of vehicle or the combination of 10 *μ*M treprostinil and 30 *μ*M forskolin at 37°C for 1 hour and 24 hours. After washing with phosphate-buffered saline at 4°C, cells were stained for externalized phosphatidylserine with the PE Annexin-V Apoptosis Detection Kit I according to the manufacturer's protocol or for DNA content with propidium iodide (50 *μ*g ml^−1^ in phosphate-buffered saline) for 40 minutes at 37°C. Data obtained by flow cytometry were analyzed with FACSDiva Software. Colony formation of murine HSPCs was determined as follows: After an incubation for 1 hour in the presence of 10 *μ*M treprostinil and 30 *μ*M forskolin, cells were resuspended in MethoCult containing granulocyte-macrophage colony-stimulating factor and IL-3 (10 ng ml^−1^ each) for the formation of granulo-monocytic colony--forming units and 3 IU ml^−1^ of erythropoietin and IL-3 for erythroid colony forming units and cultured at 37°C and 5% CO~2~ for 7--10 days. The number of colonies was counted under a light microscope.

### Expression of CXCR4. {#s10}

Human HSPCs were isolated from umbilical cord blood and subsequently incubated in the absence and presence of the combination of treprostinil (10 *μ*M) and forskolin (30 *μ*M) for 1--6 hours at 37°C. Subsequently, cells were washed and either lysed in TRIzol to isolate RNA or stained with the FITC-labeled 4H11-antibody against CD34 and the allophycocyanin-labeled 12G5-antibody against CXCR4/CD184. Dual-labeled cells were gated to quantify the surface expression of CXCR4 in a FACSCanto II (Becton, Dickinson and Company, Franklin Lakes, NJ).

### Migration Assay. {#s11}

Chemotaxis toward SDF-1 was determined using a two-chamber Transwell system. After in vitro stimulation and washing steps, cells were resuspended to obtain a suspension of about 2 × 10^6^ cells ml^−1^ in StemSpan SFEM containing growth factors. The cell suspension (0.1 ml) was added to the upper chamber with or without 100 ng ml^−1^ SDF-1 in the lower chamber. After 4 hours at 37°C, the number cells that had migrated into the lower chamber was counted in a Luna automated cell counter (Logos Biosystems, Annandale, VA) and was expressed as percentage of the total cells originally added to the upper chamber. Assays were done in triplicate.

### Transplantation of Murine and Human HSPCs. {#s12}

BALB/c, C57BL/6J (CD45.2+), B6.SJL-PtrcAPep3B/BoyJ (CD45.1^+^), and NOD/SCID/IL-2Rg2/2 (NSG) mice were obtained from the Jackson Laboratory (Bar Harbor, ME) through Charles River Germany (Sulzfeld, Germany). Six-to-eight-week-old female and male mice with mean body weight of 20--25 g were used. Housing and husbandry was in accordance with the recommendations and requirements as defined by the Federation of Laboratory Animal Science Associations (FELASA) in Europe. Mice were kept in specific pathogen-free conditions in isolated ventilated cages \[≤5 mice/cage; SmartFlow and EasyFlow (Tecniplast, Buguggiate, Italy)\], the light/dark cycle was 12 hours, animal holding rooms were maintained at 21 ± 3°C, autoclaved food (pellets enriched with vitamins), and water was provided ad libitum. Animal welfare and health status were checked by animal technicians under the supervision of a veterinarian. Sample-size calculations were made on the basis of published reports ([@B2]; [@B1]; [@B18]) and on the assumption that statistically significant (*P* \< 0.05) differences were to be detected with a power of 95%. This condition was met with ten mice per group. The experimental protocol was reviewed by the animal ethics committee and approved by the Austrian Ministry of Science and Research (BMWF-66.009/0164-II/10b/2010) for compliance with the pertinent Austrian laws, which follow the 2010/63/EU Directive. The protocol involving human umbilical cord blood samples was approved by the Ethics Committee of the Medical University of Vienna.

All recipient mice received numbered ear tags. These numbers were randomly allocated to treatment groups (variation in cell numbers and drug regimen). The allocation was concealed from the person carrying out the tagging. The isogenic recipient mice (C57BL/6 or BALB/c) or NSG mice were subjected to lethal irradiation (9 Gy, split doses, 2 Gy min^−1^; Siemens Primus, 6MV, Siemens Austria). Mice were individually placed in chambers of an acrylic irradiation pie with 15 mice (alternating male and female) per pie. The radiation dose delivered was verified with a dosimeter. Thereafter, mice were allowed to recover from irradiation for 24 hours. Prior to transplantation, murine or human HSPCs were preincubated in the absence and presence of a combination of 10 *μ*M treprostinil and 30 *μ*M forskolin for 1 hour at 37°C. Subsequently, the incubation medium was removed by three cycles of centrifugation to avoid any carryover effects. The resuspension of HSPCs was injected via the tail vein. For transplantation of cells, syringes were filled with varying numbers of pretreated or control cells, or vehicle. Preliminary experiments defined the limiting number of HSPCs. The administered number of HSPCs ranged from 2.5 to 5 × 10^5^ per mouse and is indicated in the respective figure legends. A second person, who was blinded to the syringe content, performed the tail vein injection. In some experiments, recipient mice were also subjected to an in vivo treatment: They were injected subcutaneously with treprostinil (0.015, 0.15, and 1.5 mg kg^−1^ 8 h^−1^, starting immediately prior to transplantation of cells), or the combination of treprostinil (0.15 kg^−1^ 8 h^−1^) and AMD3100 (3.3 mg kg^−1^ 8 h^−1^) in a total volume of 80 *μ*l per mouse, for 10 days. Untreated control mice received sham-injections of equal volume. The person who injected the drugs or vehicle did not prepare the syringes and was blinded to the content. The animal technicians were blinded to the treatment and monitored the well-being of the animals. On the basis of their training they assessed the outcome as death or imminent death by deciding whether a humane endpoint had been reached. The humane endpoints included emaciation (i.e., weight loss \>30%), loss of activity (reduced mobility, prolonged crouching, etc.), loss of grooming/ruffled fur, or labored breathing. Mice meeting these criteria were killed by cervical dislocation. If not rescued by transplantation of murine or human HSPCs, irradiated mice succumbed to death within the first 2 weeks. For competitive transplantation assays, murine HSPCs were harvested from CD45.1-positive (CD45.1^+^) and CD45.2-positive (CD45.2^+^) donor mice and injected into the lethally irradiated recipient mice as outlined above. In the competitive setting, cells were also pretreated with 10 *μ*g ml^−1^ cholera toxin as a positive control. After 16 weeks, the bone marrow of recipient mice was analyzed by flow cytometry according to CD45.1 and CD45.2 surface expression.

### Secondary Transplants. {#s13}

Bone marrow cell suspensions were obtained from primary recipient mice and transplanted into lethally irradiated secondary recipients. White blood cell counts and body weight were monitored over 12 months.

Results {#s14}
=======

 {#s15}

### Treprostinil Stimulates cAMP Accumulation in Murine and Human HSPCs. {#s16}

Previous work showed that engraftment of murine HSCs was enhanced by stimulating G*α*~s~-coupled EP~2~-receptors with dmPGE~2~. We first documented that murine and human HSPCs expressed additional prostanoid receptors coupled to G*α*~s~ by PCR: Amplicons were identified for the prostanoid receptors (EP~1~, EP~2~, EP~3,~ EP~4~, IP, and DP~1~) in both murine and human HSPCs ([Fig. 1, A and B](#F1){ref-type="fig"}). The relative abundance of receptor transcripts was also estimated by quantitative PCR (qPCR; right hand numbers in [Fig. 1, A and B](#F1){ref-type="fig"}). There was some interspecies variation: The level of mRNA encoding EP~1~ receptor was substantially higher in murine cells (i.e., ΔCt ≈ 0.67 versus reference gene murine HPRT1) than in human cells (i.e., ΔCt ≈ --5.7 versus reference gene human HPRT1); this was also true for the transcripts encoding murine EP~3~- and EP~4~-receptors. In contrast, transcripts for EP~2~ and IP-receptors were found at comparable relative levels in human and murine cells. The presence of the IP-receptor suggested that synthetic prostacyclin analogs ought to raise cAMP levels in HSPCs.

![Prostanoid receptor expression (A, B) and stimulation of cAMP accumulation (C--F) in murine and human HSPCs. (A, B) RNA was isolated from murine (A) and human HSPCs (B) and reverse transcribed. RNA prepared from murine brain cells (mixed culture of neurons and glial cells) and the human prostate cancer cell lines PC3 and HCT116 served as positive controls. PCR-dependent amplification was done using primers listed in [Table 1](#T1){ref-type="table"}. Amplicons for all E prostanoid receptors (EP~1--4~, IP, and DP~1~) were electrophoretically resolved on an agarose gel and visualized by ethidium bromide staining. The lane labeled H~2~O denotes the control, where the amplification was done in the absence of prior reverse transcription. The mRNA encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified as internal reference. Quantitative PCR was performed using Maxima SYBR Green/ROX qPCR Master Mix (2×) and equal amounts of cDNAs and primers. Human and murine HPRT1 was used as reference gene for normalization of qPCR experiments. Each reaction condition was performed in triplicate. Relative abundance was calculated using the 2^--ΔCt^ method (gene-specific expression level relative to that of the endogenous reference gene HPRT1, which was set at 1). We failed to identify a primer pair capable of amplifying murine DP1 receptor transcripts with an efficiency close to 100%; accordingly, the quantification of DP1 receptor transcripts is not shown. (C--F) The cAMP response of murine (C, D) and CD34^+^ human HSPCs (E, F) was determined after metabolic labeling of the adenine nucleotide pool with \[^3^H\] adenine. In some instances (PTX), cells were concomitantly also preincubated with pertussis toxin (100 ng ml^−1^) for 16 hours. (C) Murine HSPCs were stimulated with treprostinil (10 *μ*M; Trep), iloprost (30 *μ*M), beraprost (30 *μ*M), and forskolin (30 *μ*M; Fsk) or the combination of indicated agonists and forskolin (30 *μ*M). In the presence of 10 *μ*M treprostinil, 30 *μ*M forskolin was more efficacious than 30 *μ*M iloprost and beraprost (*p* = 0.02, one-way ANOVA). (E) Human HSPCs were stimulated with treprostinil (10 *μ*M), forskolin (30 *μ*M), the combination thereof, or dmPGE~2~ (10 *μ*M), or the combination thereof with forskolin (30 *μ*M). Both, in the absence and presence of 30 *μ*M forskolin, 10 *μ*M treprostinil was more efficacious than 10 *μ*M dmPGE~2~ (*p* = 0.03; Wilcoxon test). In contrast, in cells, which had been pretreated with pertussis toxin, stimulation with forskolin+treprostinil and forskolin+dmPGE2 did not result in any statistically significant difference in cAMP accumulation (*ns*). Panels D and F show the concentration-response curve for treprostinil-induced cAMP accumulation for murine (in the presence of 30 *μ*M forskolin) and human HSPCs, respectively. The maximum levels of \[^3^H\]cAMP accumulation was 595 ± 60 cpm (D) and 1943 ± 262 cpm (F). Data are means ± S.D. (*n* = 3).](mol.116.103267f1){#F1}

The adenine nucleotide pool of murine HSPCs was metabolically labeled with \[^3^H\]adenine and their response to treprostinil, iloprost, and beraprost was examined. Because these cells have a very modest cAMP response, the enzyme was sensitized by using forskolin. This diterpene binds in the pseudo substrate cleft between the catalytic C1 and C2 domains of adenylyl cyclase ([@B36]) and renders the various isoforms of the enzyme more responsive to the stimulatory G protein G*α*~s~ ([@B35]; [@B23]). As can be seen from [Fig. 1C](#F1){ref-type="fig"}, 10 *μ*M treprostinil, 30 *μ*M beraprost, and 30 *μ*M iloprost per se caused a modest accumulation of cAMP in murine HSPCs that was comparable in magnitude to that elicited by 30 *μ*M forskolin. However, when combined with 30 *μ*M forskolin, 10 *μ*M treprostinil caused an increase in cAMP levels that exceeded that caused by the IP receptor specific compounds iloprost and beraprost. In the presence of forskolin, treprostinil caused a concentration-dependent accumulation of cAMP in murine cells ([Fig. 1D](#F1){ref-type="fig"}).

Similar experiments were performed with human HSPCs isolated from umbilical cord blood ([Fig. 1, E and F](#F1){ref-type="fig"}). Treprostinil caused an increase in cAMP levels in human HSPCs, which was enhanced by 30 *μ*M forskolin ([Fig. 1E](#F1){ref-type="fig"}). The relative effects were reasonably comparable in human and murine HSPCs (cf. [Fig. 1, C and E](#F1){ref-type="fig"}). Incubation of human HPCs with treprostinil resulted in cAMP accumulation that was robust enough to be determined in the absence of forskolin ([Fig. 1E](#F1){ref-type="fig"}). The most conspicuous finding was the observation that the concentration-response curve of treprostinil (EC~50~ = ∼5 *μ*M; [Fig. 1F](#F1){ref-type="fig"}) spanned more than two orders of magnitude (Hill coefficient = 0.55). This indicates that more than one receptor subtype is involved. Finally, it was of interest to compare cAMP elevations elicited by dmPGE~2~ and by treprostinil: In the presence of 30 *μ*M forskolin, stimulation by 10 *μ*M treprostinil resulted in significantly higher cAMP than 10 *μ*M dmPGE~2~ ([Fig. 1E](#F1){ref-type="fig"}). The lower efficacy of dmPGE~2~ can be rationalized by taking into account that dmPGE~2~ is also a full agonist at the G~i~-coupled EP3 receptor ([@B39]) and thus causes both, a G~s~-dependent stimulation of adenylyl cyclase via EP~2~ and EP~4~ receptors and a concomitant inhibition via G~i~-coupled EP~3~-receptors. Pertussis toxin abolishes the interaction of G~i~-coupled receptors with G~i~ (and related G proteins such as G~o~ and G~t~) by ADP-ribosylating a cysteine residue four amino acids removed from the C-terminus of the G*α*~i~-subunit. Accordingly, HSPCs were preincubated for 16 hours in the presence of pertussis toxin. This pretreatment increased the response to dmPGE~2~ (cf. 6th and 9th bar in [Fig. 1E](#F1){ref-type="fig"}) such that there was no significant difference between the cAMP response elicited by treprostinil + forskolin and that caused by dmPGE~2~ + forskolin (cf. 8th and 9th bar in [Fig. 1E](#F1){ref-type="fig"}). Substantially lower EC~50~-values (i.e., in the nanomolar range) have been reported, if treprostinil was tested on cell lines overexpressing individual human prostanoid receptors. The reason for the discrepancies between our *μ* molar EC~50~ values and those reported by [@B37] is not clear, but we suspect that the very high receptor levels achieved by heterologous overexpression resulted in a substantial leftward shift of the concentration-response curve.

### Pretreatment of HSPCs with Treprostinil and Forskolin Does Not Alter Cell Viability, Cell Cycle Progression, or Differentiation Potential. {#s17}

A persistent elevation in cAMP may trigger apoptosis in hematopoietic cells ([@B20]). We thus examined whether in vitro pretreatment of human HSPCs with the combination of 30 *μ*M forskolin and 10 *μ*M treprostinil rendered cells more susceptible to apoptosis ([Fig. 2, A and B](#F2){ref-type="fig"}) or impeded their entry into and progression through the cell cycle ([Fig. 2, C and D](#F2){ref-type="fig"}) or altered the ability of murine HSPCs to give rise to specific lineages ([Fig. 2, E and F](#F2){ref-type="fig"}). As illustrated by the original dot plots ([Fig. 2A](#F2){ref-type="fig"}) and summarized in [Fig. 2B](#F2){ref-type="fig"}, the presence of viable, early apoptotic and dead cells was comparable and the number of annexin-V positive cells was not increased upon in vitro treatment with 30 *μ*M forskolin and 10 *μ*M treprostinil. Likewise, the cell cycle distribution of asynchronously growing untreated human HSPCs and HSPCs maintained in the presence of treprostinil and forskolin was comparable, regardless of whether HSPCs were exposed for 1 hour or 24 hours (cf. [Fig. 2C](#F2){ref-type="fig"} for representative original histograms and [Fig. 2D](#F2){ref-type="fig"} for averaged data). Importantly we also failed to detect any effect of treprostinil and forskolin on the formation of myeloid and erythroid colonies: Murine HSPCs were isolated from bone marrow, incubated for 1 hour in the presence of treprostinil and forskolin, and resuspended in a methylcellulose-containing medium with growth factors required for supporting the differentiation and growth of colony-forming units of the CFU-GM and of the BFU-E. After 10 days, the morphology ([Fig. 2E](#F2){ref-type="fig"}) and the number of colonies were comparable ([Fig. 2F](#F2){ref-type="fig"}).

![Pretreatment of murine and human HSPCs with treprostinil and forskolin does neither induce apoptosis nor alters cell cycle progression or differentiation potential. Human HSPCs were incubated with 10 *μ*M treprostinil and 30 *μ*M forskolin for 1h. Subsequently, (A, B) apoptosis induction and (C, D) cell cycle progression was assessed by flow cytometric analysis. Representative original pictures are depicted (A, C, left hand panel) and data obtained in three independent experiments was summarized (B, D, right hand panel). No difference in apoptotic cells or distribution of cells according to G~0/1~, S and G~2~ phase was detected between untreated and treated cells (one way ANOVA). (E, F) Murine HSPCs were isolated form bone marrow, pretreated and resuspended in a methylcellulose medium containing growth factors required for supporting the differentiation and growth of granulo-monocytic colony--forming units (CFU-GM) and of the erythrocyte lineage (BFU-E, burst-forming-unit erythroid). After 10 days the number of colonies was counted under a light microscope and shape and morphology of colonies was observed. Shown are representative photomicrographs and the quantification of three independent experiments. Data are means ± S.E.M. (*n* = 3).](mol.116.103267f2){#F2}

### Pretreatment of Murine HSPCs with Treprostinil and Forskolin Enhances Bone Marrow Reconstitution. {#s18}

Activation of G*α*~s~ is predicted to enhance the ability of HSPCs to repopulate the bone marrow ([@B1]). Thus, upon pretreatment with treprostinil and forskolin, HSPCs ought to be more effective than unstimulated cells in reconstituting the bone marrow of lethally irradiated recipient mice. We verified this conjecture by isolating murine HSPCs either from C57BL/6 (CD45.2^+^) or B6.SJL-PtrcAPep3B/BoyJ (CD45.1^+^) mice. Prior to transplantation, donor cells were pretreated in vitro for 1 hour in the presence of treprostinil and forskolin. Standard medium alone was used as negative control (internal control cells in [Fig. 3](#F3){ref-type="fig"}); CTX served as positive control. The use of CD45.1^+^ and CD45.2^+^ HSPCs allowed for differentiating the effects of the pretreatment on bone marrow reconstitution in a competitive setting: Either the CD45.1^+^ cells were pretreated and the CD45.2^+^ cells were incubated in medium as unstimulated control ([Fig. 3, A and C](#F3){ref-type="fig"}) or vice versa ([Fig. 3, B and D](#F3){ref-type="fig"}). Sixteen weeks after transplantation, the contribution of either donor cell type was assessed by analyzing surface expression of CD45.1 and CD45.2 on bone marrow cells of recipient mice by flow cytometry. Representative original data for each experiment are shown in [Fig. 3A](#F3){ref-type="fig"} and [Fig. 3B](#F3){ref-type="fig"}: The upper panels document the competitive bone marrow reconstitution without prestimulation of either donor cell type. In the corresponding lower panels, either CD45.1^+^ ([Fig. 3A](#F3){ref-type="fig"}) or CD45.2^+^ ([Fig. 3B](#F3){ref-type="fig"}) HSPCs were prestimulated by treprostinil and forskolin and allowed to compete with unstimulated CD45.2^+^ and CD45.1^+^ HSPCs. The outcome of HSPC transplantation is limited---at least in part---by the number of available cells ([@B28]). Accordingly, we lowered the number of administered HSPCs from a total of 10^6^ cells/mouse (CD45.1^+^/CD45.2^+^ = 1:1 in [Fig. 3, A and C](#F3){ref-type="fig"}) to 5 × 10^5^ cells/mouse and changed the ratio (CD45.1^+^/CD45.2^+^ = 10:1, [Fig. 3, B and D](#F3){ref-type="fig"}). In the absence of any stimulation, the vast majority of reconstituted bone marrow cells originated from the injected untreated CD45.1^+^ HSPCs (left hand set of bars labeled "internal control" in [Fig. 3 D](#F3){ref-type="fig"}). In contrast, if the CD45.2^+^ HSPCs were stimulated with treprostinil and forskolin (or with CTX) and then combined with the 10-fold excess of unstimulated CD45.1^+^ cells, they effectively competed for the bone marrow niche such that they gave rise to the vast majority of bone marrow cells in recipient animals (right hand set of bars in [Fig. 3D](#F3){ref-type="fig"}). Thus, the effectiveness of pretreatment was most evident at low cell numbers. Of note, the effect size of treprostinil and forskolin was comparable in magnitude to that of CTX (left hand set of bars in [Fig. 3, C and D](#F3){ref-type="fig"}).

![Competitive advantage of HSPCs after pretreatment with the combination of treprostinil and forskolin or cholera toxin over unstimulated controls. Murine HSPCs were isolated from CD45.1^+^ and from CD45.2^+^ donor mice. Either CD45.1^+^ (A, C) or CD45.2^+^ (B, D) cells were incubated for 1 hour in medium in the absence of any additional stimulus, in the presence of the combination of 10 *μ*M treprostinil and 30 *μ*M forskolin (Trep + Fsk, pretreated) or of 10 *μ*g ml^−1^ cholera toxin (as a positive control). First, cell suspensions were prepared that contained either equivalent amounts of both unstimulated CD45.1^+^ and CD45.2^+^ cells \[top panel in (A); bars labeled "internal control" in (C)\] or equivalent amounts of stimulated and untreated donor cells \[bottom panel in (A)\]. These suspensions containing a total of 10^6^ cells were administered by tail vein injection to lethally irradiated recipients (A, C). Conversely, CD45.2^+^ cells, which were either not stimulated \[top panel in (B); bars labeled "internal control" in (D)\], or stimulated \[bottom panel in (B)\], and untreated CD45.1^+^ were mixed at a ratio of 1:10; a total of 5 × 10^5^ cells were injected into recipient mice (B, D). The proportion of bone marrow cells arising from the two sources was determined by flow cytometry 16 weeks after transplantation. Representative original dot plots are shown in (A) and (B); bar diagrams in (C) and (D) represent the means ± S.E.M. (*n* = 5 animals per group) from two independent experiments. The indicated statistical comparisons of CD45.2- (+) and CD45.1-positive cells (\*) were done by analysis of variance (ANOVA) followed by Tukey's multiple comparison (*P* = 0.0001).](mol.116.103267f3){#F3}

### Defining the Optimal Regimen for Rescuing Lethally Irradiated Recipient Mice by Treprostinil-Treated Murine HSPCs. {#s19}

Rescue of lethally irradiated mice by transplantation depends on the cell number of transplanted HPSCs ([@B28]). Under the conditions employed, a minimum of 5 × 10^5^ was required: Six out of six transplanted animals survived, but survival decreased upon transplantation of lower cell numbers. If cell numbers were lowered to 3 × 10^5^ HSPCs, the vast majority of these animals (i.e., seven out nine) did not survive (black line in [Fig. 4](#F4){ref-type="fig"}). In contrast, seven of 13 recipient mice survived if the murine HSPCs had been stimulated with the combination of treprostinil and forskolin in vitro for 1 hour prior to injection (grey line in [Fig. 4](#F4){ref-type="fig"}). We surmised that prolonged stimulation of HSPCs provided an additional benefit. Accordingly, recipient mice were administered 0.15 mg kg^−1^ treprostinil by subcutaneous injection immediately prior to transplantation of pretreated HSPCs and every 8 hours for the next 10 days. This dose was selected on the basis of its approved indication in pulmonary hypertension. The human dose was converted to its murine equivalent on the basis of the allometric relation ([@B29]). This treatment regimen gave the best outcome: All animals survived (red line in [Fig. 4](#F4){ref-type="fig"}). The difference between the survival curves of group 2 and group 3 was statistically significant. Additional control experiments included sole in vivo administration of treprostinil (0.15 mg kg^−1^ 8 h^−1^) to recipient mice did not rescue mice from lethal irradiation. This ruled out that treprostinil facilitated recovery from hematopoietic injury or protected mice from lethal irradiation ([@B19]). Sole in vivo administration of treprostinil (0.15 mg kg^−1^ 8 h^−1^) did not rescue recipient mice transplanted with limited cell numbers (2 × 10^5^ cells). All mice, which had been only treated in vivo (five of five without transplantation and five of five with a transplantation of untreated cells) died within the first 10 days after lethal irradiation (not shown). We explored the dose range required to elicit the additional beneficial effect of s.c. treprostinil by varying the administered dose over two orders of magnitude. Thus, the intermediate dose of 0.15 mg kg^−1^ 8 h^−1^ (group 4, red line in [Fig. 5](#F5){ref-type="fig"}) was compared with the low dose 0.015 mg kg^−1^ 8 h^−1^ (group 3, gray line in [Fig. 5](#F5){ref-type="fig"}) and to the high dose 1.5 mg kg^−1^ 8 h^−1^ (group 5, green line in [Fig. 5](#F5){ref-type="fig"}). The experiment was designed to investigate the dose range in which the in vivo administration of treprostinil was safe and advantageous when compared with sole in vitro incubation of hematopoietic progenitor cells with treprostinil and forskolin. Thus, the crucial parameter was the fate of those mice allocated to groups 3--5. These had been treated in vivo with treprostinil as opposed to recipient mice allocated to group 1 (untreated) and group 2 (which did not receive any in vivo treatment). It is obvious from [Fig. 5A](#F5){ref-type="fig"} that the mice in groups 3--5 benefitted compared with untreated mice (group 1). The crucial outcome is survival after 60 days, because it reflects successful bone marrow engraftment. We therefore replotted the data to visualize the effect of treprostinil on outcome in [Fig. 5B](#F5){ref-type="fig"}. The data obtained with the high dose (1.5 mg kg^−1^ 8 h^−1^) allowed for the definition of a safety margin of 10 for treprostinil: Whereas this dose was less effective than the standard dose, it was not inferior to sole in vitro treatment (group 2) and there was no evidence for overt toxicity.

![Survival curves for lethally irradiated BALB/c mice after transplantation with murine HSPCs, which had been left untreated, treated with the combination of treprostinil and forskolin and further stimulated by in vivo administration of treprostinil. Murine HSPCs were incubated in the absence (no treatment; *n* = 9) or presence of the combination of 10 *μ*M treprostinil and 30 *μ*M forskolin (in vitro pretreatment); subsequently, the cell suspension (3 × 10^5^ cells per mouse) was administered by tail vein injection to lethally irradiated recipient mice. Some mice, which received pretreated cells, were also treated in vivo with treprostinil (in vitro and in vivo treatment; *n* = 10; 0.15 mg kg^−1^ s.c for 10 days), whereas others received no further treatment (in vitro pretreatment; *n* = 13). The differences between the survival curves are statistically significant: in vitro pretreatment versus in vitro/in vivo treatment, *P* = 0.01290; untreated control versus in vitro/in vivo treatment, *P* = 0.0003 (log-rank test).](mol.116.103267f4){#F4}

![In vivo administration of treprostinil enhances survival of recipient mice. Kaplan-Meier plots for survival of lethally irradiated recipient mice receiving 2 × 10^5^ untreated murine HSPCs (group 1, *n* = 12), HSPCs that had been solely pretreated in vitro with the combination of treprostinil and forskolin (group 2, *n* = 13), or mice that were transplanted with pretreated murine HSPC and administered---in addition---treprostinil by subcutaneous injection (group 3: 0.015 mg kg^−1^, *n* = 12; group 4: 0.15 mg kg^−1^, *n* = 14; group 5: 1.5 mg kg^−1^, *n* = 14). The experiment was performed as outlined in the legend to [Fig. 4](#F4){ref-type="fig"} and in *[Materials and Methods](#s2){ref-type="sec"}*. In panel (B), survival is replotted as a function of the administered treprostinil dose to illustrate the bell-shaped nature of the concentration-response curve. The statistical comparison was done by a Cox proportional hazard regression analysis: There was a dose-dependent effect of treprostinil on survival; however, the relation was bell-shaped: at the highest dose (1.5 mg kg^−1^ 8 h^−1^), survival was lower than at the intermediate dose (0.15 mg kg^−1^ 8 h^−1^). The Cox proportional hazard regression analysis identified the effect of different treatment regimens on survival. Treatment groups were modeled as a categorical predictor variable. Regression was performed using IBM SPSS Statistics 20.0. Omnibus Test revealed that the inclusion of the covariate "treatment group" was of high statistical significance: The decrease in hazard ratio displayed treatment dependence (see tabulated values). Compared with the "no treatment" control (group 1), the risk of fatal events decreased progressively from group 2 (sole in vitro treatment) to group 4 (additional in vivo treatment with the standard treprostinil dose). This trend leveled off and declined in animals exposed to a high treprostinil dose (group 5) as expected from a bell shaped dose-response relationship.](mol.116.103267f5){#F5}

### Secondary Transplants of Treprostinil-Treated Bone Marrow Provide Formal Proof For Safety. {#s20}

HSPCs have a (quasi-infinite) capacity for self-renewal. Secondary transplants provide formal proof that murine HSPCs repopulated the bone marrow of primary recipients. In addition, secondary transplants allow for detecting detrimental effects: e.g., ex vivo manipulations of HSPCs may limit their capacity for long-term self-renewal. Accordingly, we collected bone marrow cells 160 days after transplantation from primary recipient mice of groups 4 and 5 of the experiment depicted in [Fig. 5](#F5){ref-type="fig"}, because they had received HSPCs, which were pretreated in vitro and had also been exposed in vivo to the standard dose (0.15 mg kg^−1^ 8 h^−1^) and the high dose of treprostinil (1.5 mg kg^−1^ 8 h^−1^). If bone marrow cells isolated from those first recipients were administered to lethally irradiated mice, these secondary recipients were rescued and all mice survived more than 150 days: Hematopoiesis was restored; white blood cell counts reached normal levels within 30 days and were maintained for the entire observation period ([Fig. 6](#F6){ref-type="fig"}, upper panel). Likewise, the animals thrived after the initial radiation sickness-induced drop in body weight ([Fig. 6](#F6){ref-type="fig"}, lower panel) and we did not find any signs of overt pathology over an observation period of more than 400 days.

![Time-dependent change in peripheral white blood cell counts (upper graph) and body weight (lower graph) after transplantation of bone marrow cells obtained from primary recipients. One-hundred, sixty days after transplantation four mice originating from treatment group 4 and group 5 respectively, were sacrificed, their femurs were flushed with phosphate-buffered saline to recover bone marrow cells. Subsequently, 2 × 10^6^ bone marrow cells were transplanted into lethally irradiated secondary recipient mice. All mice that received this secondary transplant survived. At the indicated time points, blood was drawn, the white blood cell count was determined, and the weight of the mice recorded. Data are means ± S.E.M.](mol.116.103267f6){#F6}

### Rescue of Lethally Irradiated NSG Mice by Treprostinil-Stimulated Human HSPCs. {#s21}

Human HSPCs also express several G~s~-coupled prostanoid receptors and treprostinil treatment increases cAMP levels in these cells (cf. [Fig. 1, E and F](#F1){ref-type="fig"}). We therefore hypothesized that treprostinil also stimulated the engraftment of human HSPCs. Accordingly, CD34^+^ human HPSCs were isolated from umbilical cord blood and injected into lethally irradiated NSG mice. Their bone marrow niche is permissive to engraftment of human HSPCs ([@B32]). The experimental design recapitulated that outlined for murine HSPCs in [Fig. 4](#F4){ref-type="fig"}: The number of CD34^+^ was titrated from 2.5 × 10^5^ ([Fig. 7A](#F7){ref-type="fig"}) or from 2 × 10^5^ ([Fig. 7B](#F7){ref-type="fig"}) to 1.5 × 10^5^ per mouse ([Fig. 7C](#F7){ref-type="fig"}). Three conditions were examined, namely transplantation of human CD34^+^ cells, which had been incubated in vitro in the presence of vehicle (group 1, black lines in [Fig. 6](#F6){ref-type="fig"}) or stimulated in vitro with treprostinil and forskolin (group 2, gray lines in [Fig. 6](#F6){ref-type="fig"}) and where the recipient NSG mice were subsequently administered s.c. 0.15 mg kg^−1^ 8 h^−1^ treprostinil for 10 days (group 3, red lines in [Fig. 7](#F7){ref-type="fig"}). The fate of recipient mice, which were injected with untreated human HSPCs (group 1 in [Fig. 6](#F6){ref-type="fig"}), depended on the number of cells: 40% and 20% survived upon injection of 2.5 × 10^5^ ([Fig. 7A](#F7){ref-type="fig"}) and 2 × 10^5^ cells ([Fig. 7B](#F7){ref-type="fig"}), respectively, but all died within the first ten days if they were injected 1.5 × 10^5^ cells ([Fig. 7C](#F7){ref-type="fig"}). This dependence on cell number was also seen, if the human HSPCs had been pretreated in vitro (group 2, gray curves in [Fig. 7](#F7){ref-type="fig"}), but it was less evident for those mice administered s.c. 0.15 mg kg^−1^ 8 h^−1^ treprostinil over ten days (group 3, red curves in [Fig. 7](#F7){ref-type="fig"}). Importantly, even at the lowest cell number, 4 out 5 mice survived, if they received treprostinil in vivo, whereas all group 2 mice died ([Fig. 7 C](#F7){ref-type="fig"}). Conversely, at the high cell number, sole in vitro pretreatment rescued all animals ([Fig. 7 A](#F7){ref-type="fig"}); it is obvious that under these conditions, the additional in vivo administration of treprostinil cannot provide any further benefit. The statistical comparisons (tabulated in [Fig. 7](#F7){ref-type="fig"}) also document that the difference between the three conditions is most readily appreciated at low cell numbers.

![Survival curves for lethally irradiated NSG mice after transplantation with different amounts of human HSPCs. CD34^+^ human hematopoietic progenitor cells were isolated from umbilical cord blood and incubated in the absence (no treatment, group 1) or presence of the combination of treprostinil and 30 *μ*M forskolin (in vitro pretreatment, groups 2 and 3); subsequently, the cell suspension (2.5 × 10^5^, 2 × 10^5^, and 1.5 × 10^5^ cells per mouse in the (A), (B), and (C) panels, respectively) was administered by tail vein injection to lethally irradiated recipient NSG mice. Some mice, which received pretreated cells, were also treated in vivo with treprostinil (in vitro and in vivo treatment, group 3; 0.15 mg kg^−1^ 8 h^−1^, s.c. and for 10 days), whereas others received no further treatment (in vitro pretreatment -- group 2). Each group was comprised of 5 animals. The tables summarize the comparisons of the individual Kaplan-Maier plots by log-rank test.](mol.116.103267f7){#F7}

### The Beneficial Action of Treprostinil Is Contingent on SDF-1. {#s22}

Enhanced engraftment of dmPGE~2~-treated HSCs was attributed to effects on cell survival, proliferation, and homing ([@B18]). The SDF-1/CXCR4 axis plays a major role in homing of HSCPs to the bone marrow niche. Under our experimental conditions, in vitro pretreatment of murine and human HSPCs with treprostinil and forskolin enhanced bone marrow reconstitution but did not alter cell viability or cell cycle progression in vitro *(*cf. [Fig. 3](#F3){ref-type="fig"}). Thus we surmised that the beneficial action of treprostinil resulted from enhanced engraftment of HSPCs through SDF-1/CXCR4--mediated effects. This conjecture was examined as follows: Prestimulation of human HSPCs with treprostinil and forskolin raised mRNA levels ([Fig. 8A](#F8){ref-type="fig"}) and surface levels of CXCR4 ([Fig. 8, B and C](#F8){ref-type="fig"}). The upregulation of CXCR4 was translated into enhanced migration of human ([Fig. 8D](#F8){ref-type="fig"}) and murine ([Fig. 8E](#F8){ref-type="fig"}) HSPCs toward SDF-1. This directed migration was specific, because it was blocked by the selective CXCR4-antagonist plerixafor/AMD3100 ([@B16]) ([Fig. 8F](#F8){ref-type="fig"}). Likewise, basal migration (i.e., random migration in the absence of SDF-1) was not enhanced by pretreating HSPCs with treprostinil and forskolin (cf. first and third bar in [Fig. 8, B and C](#F8){ref-type="fig"}). The antagonism by AMD3100 was recapitulated in vivo: The bone marrow of lethally irradiated recipient mice was reconstituted with treprostinil- and forskolin-pretreated HSPCs, and the mice were subsequently administered subcutaneously the optimum dose of treprostinil for 10 days. The concomitant administration of AMD3100 (3.3 mg kg^−1^ 8 h^−1^) blunted the beneficial action of treprostinil so that all recipient mice eventually succumbed to bone marrow failure ([Fig. 9](#F9){ref-type="fig"}). Thus, taken together, the observations indicate a mechanistic link between treprostinil-induced cAMP accumulation and enhanced CXCR4-signaling in HSPCs.

![In vitro pretreatment with treprostinil and forskolin enhances the action of SDF-1 via CXCR4. (A) RNA was isolated from human HSPCs that had been incubated in the absence (control) or presence of the combination of 10 *μ*M treprostinil and 30 *μ*M forskolin (Trep + Fsk) for 1 hour. RNA prepared from the human prostate cancer cell line PC3 served as positive control. After reverse transcription, PCR-dependent amplification was done using primers listed in [Table 1](#T1){ref-type="table"}. Amplicons for CXCR4 were electrophoretically resolved on an agarose gel and visualized by ethidium bromide staining. The mRNA encoding *β*-actin was amplified as internal control. The data are representative of two additional experiments with similar results. (B, C) Human HSPCs were incubated in the absence (red trace = vehicle control) or in the presence of the combination of treprostinil (10 *μ*M) and forskolin (30 *μ*M) for 2 hours (blue trace), 4 hours (orange trace), and 6 hours (green trace) at 37°C and stained for CXCR4 with an allophycocyanin-labeled antibody. (B) FACS histograms from a representative experiment. (C) Bar diagram shows means ± S.E.M. from three independent experiments. Statistically significant differences were examined using repeated-measures ANOVA followed by Bonferroni's multiple comparison. (D--F) Freshly isolated murine and human HPSC were pretreated in vitro with either vehicle (open bars) or 10 *μ*M treprostinil and 30 *μ*M forskolin (closed bars) for 1 hour at 37°C followed by washing steps. A suspension (2 × 10^5^ cells in 0.1 ml of medium containing growth factors) of human (D) or murine HSPCs (E, F) was added to the upper chamber of a Transwell and allowed to migrate toward SDF-1 (100 ng ml^−1^ in the lower chamber) for 4 hours. Cells that had migrated through the 5-*μ*m filter were counted. HSPCs were also incubated in the absence and presence of 10 *μ*M AMD3100 to confirm that the effects arose from a stimulation of CXCR4 (F). Data represent ± S.E.M. from three independent experiments carried out in triplicate. The statistical comparison was done by repeated-measures ANOVA followed by Tukey's multiple comparison (\**P* \< 0.05, \*\**P* \< 0. 01, \*\*\**P* \< 0.001).](mol.116.103267f8){#F8}

![In vivo administration of CXCR4-antagonist (AMD3100) abrogates the beneficial effect of treprostinil on the survival of recipient mice. Murine HPSCs were pretreated in vitro with treprostinil and forskolin as outlined in the legend to [Fig. 4](#F4){ref-type="fig"} and injected (2 × 10^5^ per mouse) into lethally irradiated recipient mice. These were subsequently divided into two groups. Mice allocated to group 1 (*n* = 10) were further subjected to in vivo treatment with treprostinil (0.15 mg kg^−1^), and mice in group 2 (*n* = 10) received both treprostinil (0.15 mg kg^−1^ 8 h^−1^) and AMD3100 (3.3 mg kg^−1^ 8 h^−1^) by subcutaneous injection every 8 hours for 10 days. The difference between the two survival curves was statistically significant (*P* = 0.007, log-rank test).](mol.116.103267f9){#F9}

Discussion {#s23}
==========

Patients undergoing HSC transplantation incur a high risk of life-threatening infections as long as their white blood cell count remains low ([@B38]; [@B9]). Thus, there is an unmet medical need to accelerate bone marrow recovery. In theory, this can be achieved by increasing the number of transplanted stem cells, because this augments the likelihood of their engraftment. In practice, the supply of HSCs is limited. Hence, pharmacological manipulations are of interest, if they safely enhance bone marrow engraftment. Several strategies can be envisioned, but their translation into clinical application would probably require several years ([@B26]; [@B34]; [@B27]). Our approach assumes that, among several candidate pathways, G*α*~s~-stimulated cAMP accumulation would most probably identify a safe drug suitable for translation into clinical application for the following reasons: 1) The pathway can be stimulated via G~s~-coupled receptors, which can be identified by cataloging their expression and by verifying that their stimulation raises cAMP in HSPCs ([@B4]). Agonists can be selected on the basis of their clinical safety profile. 2) In vitro, the action of agonists can be greatly augmented by using forskolin ([@B35]; [@B23]). Thus, in the presence of forskolin, agonists can raise cAMP to levels comparable to or exceeding those achieved by cholera toxin. Cholera toxin provides a reference point for gauging drug efficacy, because it was shown to enhance the capacity of HSPCs to reconstitute hematopoiesis ([@B1]). With this strategy, we identified treprostinil as a candidate drug suitable for improving human HSC transplantation on the basis of the following observations: Murine and human HSPCs expressed mRNAs encoding several G~s~-coupled prostanoid receptors (i.e., DP~1~-, IP-, EP~2~-, and EP~4~-receptor). Treprostinil is an agonist at all these receptors ([@B5]; [@B37]). Consistent with its broad pharmacological profile, treprostinil was more efficacious in stimulating cAMP accumulation than the IP receptor--selective agonists beraprost and iloprost ([@B4]). Murine and human HSPCs tolerated treprostinil and forskolin without any detectable effect on their viability and their ability to undergo asymmetric cell division and lineage-specific differentiation. 3) Pretreating murine and human HSPCs with treprostinil and forskolin enhanced their engraftment in lethally irradiated recipient mice. The combination was as efficacious as the pretreatment with cholera toxin. 4) The additional treatment of recipient mice with treprostinil in vivo further enhanced bone marrow engraftment.

Prostanoids play a crucial role in regulating vertebrate HSCs; this was first appreciated in zebra fish ([@B24]). Accordingly, dmPGE~2~ promotes engraftment of HSCs ([@B12]; [@B18]; [@B14]). In fact, in a phase I trial, the period of neutropenia was shortened by some 3.5 days, if human cord blood cells were preincubated with dmPGE~2~ prior to their administration to recipients ([@B10]). On the basis of our observations, we propose treprostinil as an alternative suitable for promoting bone marrow engraftment in human recipients for the following reasons: the beneficial effect resulting from in vitro pretreatment of HSPCs with the combination of treprostinil and forskolin was further augmented by administering treprostinil to recipients over several days; and treprostinil was approved for the treatment of pulmonary hypertension in 2002. Thus, the clinical experience with treprostinil covers many thousands of patient years, and its safety profile is well understood. This also includes long-term data in both adults ([@B30]; [@B6]) and children ([@B33]). It is therefore reasonable to posit that treprostinil can be repurposed and safely administered to patients undergoing HSC transplantation. It is worth noting that, in the optimal regimen, the HSPCs were first preincubated ex vivo with the combination of forskolin and treprostinil prior to the treatment of the recipient with treprostinil. We consider it improbable that this pretreatment with the combination of forskolin and treprostinil will be a major regulatory impediment, because forskolin is removed prior to administration of the donor HSPCs and only treprostinil is administered to the recipient. In contrast, dmPGE~2~ is not yet an approved drug, thus the dose-response relation that governs side effects in man is poorly understood. In human HSPCs, treprostinil was substantially more efficacious in raising cAMP than dmPGE~2~. This can be rationalized by taking into account that dmPGE~2~ is also a potent agonist of EP~3~-receptors ([@B39]). Concomitant stimulation of G~i~-coupled EP~3~-receptors by dmPGE~2~ is predicted to limit cAMP accumulation elicited via EP~2~- and/or EP~4~-receptors. In contrast, treprostinil is a low affinity agonist at EP~3~-receptors ([@B37]). It is also worth considering that prostanoids have multiple sites of actions in the bone marrow: Our data unequivocally showed that the additional in vivo treatment of recipient mice with treprostinil was more efficacious than sole in vitro preincubation of the HSPCs, but the dose-response curve was bell-shaped. The mechanistic basis for the bell-shaped curve is not clear. However, it is not surprising that the action of treprostinil in vivo is complex. G~s~-coupled E prostanoid receptors that are relevant to engraftment of HPSCs are not only expressed in the stem cell compartment. In fact, EP~4~ receptors are for instance, also found on the cells lining the endosteal niche ([@B17]). At the very least, our observations indicate that dmPGE~2~, which acts at EP~2~, EP~3~, and EP~4~-receptors ([@B39]), probably has several additional sites of action, which limit its application in vivo.
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